Q-omics provides the consensus-scored MAPT profile across patient tissues and cancer cell-line models. MAPT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAPT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MAPT RNA expression shows 25,011 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where MAPT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPT survival associations across molecular data types. MAPT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPT RNA expression–survival associations across cancer types. High MAPT expression shows unfavorable associations in UVM, UCEC and LIHC, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAPT RNA expression.
This table summarizes MAPT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAPT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPT shows lower tumor expression in HNSC, COAD, THCA and READ and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher MAPT RNA expression in tumor versus normal tissue (log2 FC = +1.853, t-test p < 0.001).
This table shows molecular features associated with MAPT in patient tissues and cancer cell lines. In patient samples, MAPT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
